Newtyn Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Newtyn Management’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,015,920	Closed	-$1.52M	–	83
2023 Q1	$1.52M	Sell	1,015,920 -59,080	-5%	-$79.6K	0.3%	53
2022 Q4	$1.07M	Buy	1,075,000 +475,000	+79%	+$640K	0.22%	50
2022 Q3	$1.08M	Sell	600,000 -92,799	-13%	-$269K	0.24%	52
2022 Q2	$2.01M	Buy	+692,799	New	+$1.71M	0.38%	41

Newtyn Management's TCRR Position: Q2 2023 in Review

Newtyn Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 1,015,920 shares — an estimated $1.52M sold.

Newtyn Management first reported a position in TCRR in Q2 2022 and held it in 4 quarters. The position peaked at $2.01M in Q2 2022. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Newtyn Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Newtyn Management sold 1,015,920 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1.52M.
Newtyn Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Newtyn Management's TCR2 Therapeutics Inc. Common Stock position peaked at $2.01M in Q2 2022.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Newtyn Management's 13F filing for Q2 2023, filed 14 Aug 2023.